Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
chemotherapy
clinical trials
high dose therapy
non‐Hodgkin's lymphoma
stem cell transplantation
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
31
03
2024
accepted:
13
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
aheadofprint
Résumé
The Canadian Cancer Trials Group (CCTG) LY.17 is an ongoing multi-arm randomized phase II trial evaluating novel salvage therapies compared with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in autologous stem cell transplantation (ASCT)-eligible patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL). This component of the LY.17 trial evaluated a dose-intensive chemotherapy approach using a single cycle of inpatient R-DICEP (rituximab, dose-intensive cyclophosphamide, etoposide and cisplatin) to achieve both lymphoma response and stem cell mobilization, shortening time to ASCT. This report is the result of the protocol-specified second interim analysis of the 67 patients who were randomized to either 1 cycle of R-DICEP or to 3 cycles of R-GDP. The overall response rate (ORR) was 65.6% for R-DICEP and 48.6% for R-GDP. The ASCT rate was 71.9% versus 54.3%, and 1-year progression-free survival rate was 42% versus 32%, respectively, for R-DICEP versus R-GDP. Although the improvement in ORR for R-DICEP versus R-GDP exceeded the pre-specified 10% threshold to proceed to full accrual of 64 patients/arm, higher rates of grade 3-5 toxicities, and the need for hospitalization led to the decision to stop this arm of the study. CCTG LY.17 will continue to evaluate different salvage regimens that incorporate novel agents.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hoffmann-La Roche Limited
Organisme : Canadian Cancer Society
ID : 704970
Organisme : Canadian Cancer Society
ID : 707213
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem‐cell transplantation for relapsed and refractory aggressive lymphomas: NCIC‐CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496.
Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020;26(7):1247–1256.
Vijay A, Duan Q, Henning JW, Duggan P, Daly A, Shafey M, et al. High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non‐Hodgkin lymphoma. Leuk Lymphoma. 2013;54(12):2620–2626.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
Dreger P, Corradini P, Gribben JG, Glass B, Jerkeman M, Kersten MJ, et al. CD19‐directed CAR T cells as first salvage therapy for large B‐cell lymphoma: towards a rational approach. Lancet Haematol. 2023;10:e1006–e1015.
Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, et al. Prognostic value of FDG‐PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B‐cell lymphoma. Blood. 2015;125(16):2579–2581.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second‐line tisagenlecleucel or standard care in aggressive B‐cell lymphoma. N Engl J Med. 2022;386:629–639.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second‐line treatment in patients with relapsed or refractory large B‐cell lymphoma (TRANSFORM): results from an interim analysis of an open‐label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. https://doi.org/10.1016/S0140‐6736(22)00662‐6
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B‐cell lymphoma. N Engl J Med. 2023;389(2):148–157. https://doi.org/10.1056/NEJMoa2301665
Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T‐cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139(9):1330–1339. https://doi.org/10.1182/blood.2021013289
Tian L, Li C, Sun J, Zhai Y, Wang J, Liu S, et al. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B‐cell lymphoma: a systematic review. Front Immunol. 2023;13:1041177. https://doi.org/10.3389/fimmu.2022.1041177
Oluwole OO, Patel AR, Vadgama S, Smith NJ, Blissett R, Feng C, et al. An updated cost‐effectiveness analysis of axicabtagene ciloleucel in second‐line large B‐cell lymphoma patients in the United States. J Med Econ. 2024;27(1):77–83. https://doi.org/10.1080/13696998.2023.2290832
Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, et al. Second‐line chimeric antigen receptor T‐cell therapy in diffuse large B‐cell lymphoma: a cost‐effectiveness analysis. Ann Intern Med. 2023;176(12):1625–1637. https://doi.org/10.7326/M22‐2276
Lemoine J, Bachy E, Cartron G, Beauvais D, Gastinne T, di Blasi R, et al. Nonrelapse mortality after CAR T‐cell therapy for large B‐cell lymphoma: a LYSA study from the DESCAR‐T registry. Blood Adv. 2023;7(21):6589–6598. https://doi.org/10.1182/bloodadvances.2023010624
Cordas dos Santos DM, Tix T, Rejeski K. Infections drive non‐relapse mortality following CAR‐T therapy across disease entities and CAR products ‐ a meta‐analysis of clinical trials and real‐world studies. Blood. 2023;142(Supplement 1):1064. https://doi.org/10.1182/blood‐2023‐187516
Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub‐Agha I, et al. Organ complications after CD19 CAR T‐cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Front Immunol. 2023;14:1252811. https://doi.org/10.3389/fimmu.2023.1252811
Herrera AF, Chen L, Crombie JL, Cohen JB, Advani RH, LaCasce AS, et al. Polatuzumab vedotin combined with R‐ICE (PolaR‐ICE) as second‐line therapy in relapsed/refractory diffuse large B‐cell lymphoma. Blood. 2022;140(Supplement 1):1065–1067. https://doi.org/10.1182/blood‐2022‐165699
Abrisqueta P, Cordoba R, Falchi L, de Vos S, Nijland M, Offner F, et al. Subcutaneous epcoritamab + R‐Dhax/C in patients with relapsed or refractory diffuse large B‐cell lymphoma eligible for autologous stem cell transplant: updated phase 1/2 results. Blood. 2022;140(Supplement 1):1068–1069. https://doi.org/10.1182/blood‐2022‐158278